New data show Atacand together with Zestril produces tighter blood pressure control in type 2 diabetes patients

December 07, 2000

The CALM study throws important light on the potential benefits of combining a long-acting AT1-receptor blocker with a long-acting ACE inhibitor in these patients

(London, UK, 8 December 2000) - The results of the CALM (Candesartan and Lisinopril Microalbuminuria) study published today in the British Medical Journal demonstrate that AT1-receptor blockade with Atacand® (candesartan cilexetil) together with ACE inhibition with Zestril® (lisinopril) is effective in reducing blood pressure and albumin excretion in hypertensive type 2 diabetic patients with microalbuminuria and that combination treatment is more effective than either drug used alone.1 This is the first study to have investigated dual blockade of the renin angiotensin system in hypertensive type 2 diabetes patients with microalbuminuria.

Lead investigator, Professor Carl Erik Mogensen, Professor of Medicine, University Hospital, Aarhus, Denmark, said: "The CALM study provides evidence for a potential role of dual blockade of the renin angiotensin system in type 2 diabetes patients in terms of its ability to lower blood pressure effectively, a beneficial effect on albuminuria and an excellent safety profile. The use of combined treatment is worthy of further investigation."

Professor Mogensen continued: "The international guidelines for blood pressure targets in diabetic subjects have emphasised the importance of aggressive blood pressure reduction.2 We also know that the majority of patients with diabetes and hypertension require treatment with more than one antihypertensive drug to achieve tight blood pressure control.3,4 The CALM study results show that a combination of the newer AT1-receptor blocking drug, candesartan cilexetil, and the established ACE inhibitor, lisinopril, is able to reduce blood pressure considerably more than monotherapy with either drug."

The CALM study was a randomised controlled trial involving 197 patients aged 30-75 years in four countries. Both Atacand® 16 mg once daily and Zestril® 20 mg once daily had significant and similar effects on both sitting and standing diastolic and systolic blood pressures after 12 and 24 weeks' treatment.

At 24 weeks the adjusted mean reductions in sitting diastolic blood pressures were 10.4 mmHg on Atacand® (p<0.001) and 10.7 mmHg on Zestril® (p<0.001). Sitting systolic blood pressure also fell significantly on both treatments, the reduction on Atacand® being 14.1 mmHg (p<0.001) and on Zestril® 16.7 mmHg (p<0.001).

Standing diastolic and systolic blood pressures were also markedly reduced and to a similar extent by the two drugs. Atacand® and Zestril® both reduced urinary albumin/creatinine ratio. At 24 weeks there was a 24% reduction in the group of patients treated with Atacand® and a 39% reduction in the Zestril® group. The difference between the drugs was not significant.

One third of the patients in the study were treated from weeks 12 to 24 with Atacand® 16 mg once daily and Zestril® 20 mg once daily given together. This regimen resulted in a greater fall in blood pressure than monotherapy with either drug with a mean reduction of 16.3 mmHg in sitting diastolic pressure (p<0.001) and 25.3 mmHg (p<0.001) in systolic pressure. Combined treatment also significantly reduced albumin/creatinine ratio.

All treatment regimens in the CALM study were generally well tolerated. The most common adverse events during any of the treatment regimens were respiratory infection, cough and headache which occurred in less than 10% of patients. Only 14 of 197 randomised patients stopped treatment due to adverse effects during the 24-week period. No marked changes in mean values for HbA1c or any routine laboratory variables were observed.
-end-
The CALM study was sponsored by AstraZeneca. Atacand® and Zestril® are marketed by AstraZeneca. Atacand® is manufactured under licence from Takeda Chemical Industries. AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $15 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products.

For further information please contact:

Jean Kilshaw
Ketchum Alison MacKenzie
Ketchum
Tel: +44 20 7465 7050 Tel: +44 20 7465 8737
Fax: +44 20 7872 9679 Fax: +44 20 7872 9679
E-mail
jean.kilshaw@ketchumcomms.co.uk
E-mail
alison.mackenzie@ketchumcomms.co.uk

References
1. Mogensen CE et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril (CALM) study. BMJ 2000; 321: 1440-1444
2. WHO Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183
3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 707-713
4. Hansson L, Zanchetti A, Carruthers SG et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-62.

Ketchum UK

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.